WHO suspends hydroxychloroquine trials over safety concerns

A Lancet study leads to a rethink of using the drug to treat coronavirus patients - but an Australian prophylaxis trial will continue

The WHO has suspended its multinational trial of hydroxychloroquine to treat patients with COVID-19, amid growing evidence the drug increases the risk of death.

The move follows a study published in the Lancet last week showing the drug, which is indicated for treatment of malaria and autoimmune conditions, had no therapeutic benefit against COVID-19 and did more harm than good.

The WHO's decision could prompt a review of Australian-based trials, including the large Australasian COVID-19 Trial